Contact Information
Phase 1 study of 9 ING 41, a Glycogen Synthase Kinase 3 Beta (GSK 3ß) inhibitor, as a single agent or with Irinotecan in pediatric patients with refractory malignancies
Gender
Any
Age Group
Any